lenvatinib has been researched along with Rupture--Spontaneous* in 2 studies
2 other study(ies) available for lenvatinib and Rupture--Spontaneous
| Article | Year |
|---|---|
A spontaneous rupture of lung metastasis from hepatocellular carcinoma after the introduction of lenvatinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Diseases; Lung Neoplasms; Male; Phenylurea Compounds; Quinolines; Rupture, Spontaneous | 2021 |
Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
A 59-year-old man who was receiving lenvatinib as a third-line tyrosine kinase inhibitor to treat hepatocellular carcinoma and multiple bone metastases complained of general fatigue four months after starting lenvatinib. A blood examination showed unexpectedly elevated serum C-reactive protein (CRP) levels. Computed tomography (CT) revealed rupture of the gallbladder wall, indicating gallbladder perforation. After conservative treatment, the patient received lenvatinib again under informed consent; however, one month later, CT revealed repeated rupture of the gallbladder wall. Gallbladder perforation had again been induced by lenvatinib. For this reason, lenvatinib is strongly considered a causative drug for gallbladder perforation. Topics: Carcinoma, Hepatocellular; Gallbladder; Gallbladder Diseases; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Rupture, Spontaneous; Tomography, X-Ray Computed | 2020 |